Browse by author
Lookup NU author(s): Micael Karlberg, Arathi Kizhedath, Professor Jarka Glassey
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2022, The Author(s), under exclusive license to Springer Nature Switzerland AG. Monoclonal antibodies were already one of the fastest growing sectors of biopharmaceutical industry [1]. Recent research on the significant benefits of various antibodies in reducing the risks of fatality or reducing the symptoms of COVID-19, e.g., tocilizumab and sarilumab (Cortegiani et al. 2021), inevitably increases the importance of the rapid discovery of mAbs and the development of efficient manufacturing processes. Research reports frequently concentrated on the rapid discovery of new mAbs, but the developability and the manufacturability of mAbs were less explored until recently [1–4]. This chapter adopts the framework of quality by design (QbD), concentrating particularly on the model-based risk assessment of mAb developability. A case study highlights specific areas where advanced modelling approaches can contribute to speeding up the manufacturability and developability of mAbs and demonstrates the benefits and the challenges of this approach.
Author(s): Karlberg M, Kizhedath A, Glassey J
Series Editor(s): Panos Pardalos, My T. Thai
Publication type: Book Chapter
Publication status: Published
Book Title: Optimization of Pharmaceutical Processes
Year: 2022
Volume: 189
Pages: 373-391
Online publication date: 07/04/2022
Acceptance date: 02/04/2018
Series Title: Springer Optimization and Its Applications
Publisher: Springer
Place Published: Switzerland
URL: https://doi.org/10.1007/978-3-030-90924-6_14
DOI: 10.1007/978-3-030-90924-6_14
